TRCT
OPRX icon

Tower Research Capital (TRC)’s OptimizeRx OPRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$721 Sell
126
-1,703
-93% -$9.79K ﹤0.01% 4962
2026
Q1 		$11.5K Sell
1,829
-318
-15% -$2.95K ﹤0.01% 3838
2025
Q4 		$26.3K Buy
2,147
+1,156
+117% +$18.9K ﹤0.01% 2896
2025
Q3 		$20.3K Sell
991
-1,737
-64% -$27.6K ﹤0.01% 3294
2025
Q2 		$36.8K Buy
2,728
+1,515
+125% +$16.6K ﹤0.01% 3230
2025
Q1 		$10.5K Sell
1,213
-688
-36% -$4.21K ﹤0.01% 3632
2024
Q4 		$9.24K Buy
1,901
+964
+103% +$5.39K ﹤0.01% 3922
2024
Q3 		$7.23K Sell
937
-10,788
-92% -$95.9K ﹤0.01% 4064
2024
Q2 		$117K Buy
11,725
+11,223
+2,236% +$123K ﹤0.01% 2462
2024
Q1 		$6.1K Sell
502
-6,263
-93% -$90.8K ﹤0.01% 4433
2023
Q4 		$96.8K Buy
6,765
+5,432
+408% +$52.1K ﹤0.01% 2664
2023
Q3 		$10.4K Buy
1,333
+659
+98% +$7.17K ﹤0.01% 4117
2023
Q2 		$9.63K Buy
674
+59
+10% +$840 ﹤0.01% 4246
2023
Q1 		$9K Sell
615
-20,017
-97% -$335K ﹤0.01% 4522
2022
Q4 		$347K Buy
20,632
+19,364
+1,527% +$335K 0.01% 925
2022
Q3 		$19K Sell
1,268
-5,347
-81% -$106K ﹤0.01% 3981
2022
Q2 		$181K Buy
6,615
+6,137
+1,284% +$182K ﹤0.01% 1840
2022
Q1 		$18K Buy
478
+75
+19% +$3.32K ﹤0.01% 3640
2021
Q4 		$25K Sell
403
-540
-57% -$40.9K ﹤0.01% 3430
2021
Q3 		$81K Buy
943
+350
+59% +$22K ﹤0.01% 2578
2021
Q2 		$37K Sell
593
-478
-45% -$24.3K ﹤0.01% 3282
2021
Q1 		$52K Sell
1,071
-3,146
-75% -$152K ﹤0.01% 3091
2020
Q4 		$131K Sell
4,217
-11,376
-73% -$279K ﹤0.01% 2102
2020
Q3 		$325K Buy
15,593
+12,613
+423% +$217K ﹤0.01% 2113
2020
Q2 		$39K Buy
2,980
+2,730
+1,092% +$29.7K ﹤0.01% 3249
2020
Q1 		$2K Buy
250
+149
+148% +$1.41K ﹤0.01% 2613
2019
Q4 		$1K Sell
101
-992
-91% -$11.2K ﹤0.01% 3299
2019
Q3 		$16K Buy
1,093
+892
+444% +$13.8K ﹤0.01% 2623
2019
Q2 		$3K Sell
201
-71
-26% -$959 ﹤0.01% 3154
2019
Q1 		$3K Sell
272
-4,576
-94% -$59.5K ﹤0.01% 3308
2018
Q4 		$53K Buy
4,848
+3,731
+334% +$55.2K ﹤0.01% 1253
2018
Q3 		$20K Buy
+1,117
New +$14.1K ﹤0.01% 2347

Other funds holding OPRX

WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $380M AUM 20.01% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Tower Research Capital (TRC)'s OPRX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its OptimizeRx (OPRX) stake by 93% in Q2 2026, selling an estimated $9.79K and leaving 126 shares worth $721. The position accounts for ﹤0.01% of the portfolio, ranked #4962.

Tower Research Capital (TRC) first reported a position in OPRX in Q3 2018 and has held it in 32 quarters since. The position peaked at $347K in Q4 2022. 112 funds tracked by Wall St. Rank hold OPRX as of Q2 2026.

  • Tower Research Capital (TRC) held 126 shares of OptimizeRx worth $721 as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,703 OptimizeRx shares in Q2 2026, an estimated $9.79K.
  • OptimizeRx made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4962 holding.
  • Tower Research Capital (TRC) first reported a position in OptimizeRx in Q3 2018 and has held it in 32 quarters since.
  • Tower Research Capital (TRC)'s OptimizeRx position peaked at $347K in Q4 2022.
  • 112 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.